Puerarin Suppresses Glycolysis and Increases Cisplatin Chemosensitivity in Oral Squamous Cell Carcinoma via FBXW7/mTOR Signaling

References

• Hasegawa K, Fujii S, Matsumoto S, Tajiri Y, Kikuchi A, Kiyoshima T. YAP signaling induces PIEZO1 to promote oral squamous cell carcinoma cell proliferation. J Pathol. 2021;253(1):80–93. 10.1002/path.5553
   PubMed Web of Science ®Google Scholar
• Panarese I, Aquino G, Ronchi A, Longo F, Montella M, Cozzolino I, Roccuzzo G, Colella G, Caraglia M, Franco R. Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route. Expert Rev Anticancer Ther. 2019;19(2):105–19. 10.1080/14737140.2019.1561288
   PubMed Web of Science ®Google Scholar
• Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Primers. 2020;6(1):92. 10.1038/s41572-020-00224-3
   PubMed Web of Science ®Google Scholar
• Huang Z, Zhang Y, Li H, Zhou Y, Zhang Q, Chen R, Jin T, Hu K, Li S, Wang Y, et al. Vitamin D promotes the cisplatin sensitivity of oral squamous cell carcinoma by inhibiting LCN2-modulated NF-kappaB pathway activation through RPS3. Cell Death Dis. 2019;10(12):936.
   PubMed Web of Science ®Google Scholar
• Powell SF, Gold KA, Gitau MM, Sumey CJ, Lohr MM, McGraw SC, Nowak RK, Jensen AW, Blanchard MJ, Fischer CD, et al. Safety and efficacy of pembrolizumab with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma: a phase IB study. J Clin Oncol. 2020;38(21):2427–37.
   PubMed Web of Science ®Google Scholar
• Abbaszadeh Z, Çeşmeli S, Biray Avcı Ç. Crucial players in glycolysis: cancer progress. Gene. 2020;726:144158. 10.1016/j.gene.2019.144158
   PubMed Web of Science ®Google Scholar
• Kumari N, Das A, Bhatt AN. Interleukin-6 confers radio-resistance by inducing Akt-mediated glycolysis and reducing mitochondrial damage in cells. J Biochem. 2020;167(3):303–14.
   PubMed Web of Science ®Google Scholar
• Israelsen WJ, Vander Heiden MG. Pyruvate kinase: function, regulation and role in cancer. Semin Cell Dev Biol. 2015;43:43–51. 10.1016/j.semcdb.2015.08.004
   PubMed Web of Science ®Google Scholar
• Long W, Gong X, Yang Y, Yang K. Downregulation of PER2 promotes tumor progression by enhancing glycolysis via the phosphatidylinositol 3-kinase/protein kinase B pathway in oral squamous cell carcinoma. J Oral Maxillofac Surg. 2020;78(10):1780.e1–1780.e14.
   PubMed Web of Science ®Google Scholar
• Ross CD, Gomaa MA, Gillies E, Juengel R, Medina JE. Tumor grade, microvessel density, and activities of malate dehydrogenase, lactate dehydrogenase, and hexokinase in squamous cell carcinoma. Otolaryngol Head Neck Surg. 2000;122(2):195–200. 10.1016/S0194-5998(00)70238-5
   PubMed Web of Science ®Google Scholar
• He J, Song Y, Li G, Xiao P, Liu Y, Xue Y, Cao Q, Tu X, Pan T, Jiang Z, et al. Fbxw7 increases CCL2/7 in CX3CR1hi macrophages to promote intestinal inflammation. J Clin Invest. 2019;129(9):3877–93.
   PubMed Web of Science ®Google Scholar
• Liu X, Ma J, Xu F, Li L. TINCR suppresses proliferation and invasion through regulating miR-544a/FBXW7 axis in lung cancer. Biomed Pharmacother. 2018;99:9–17. 10.1016/j.biopha.2018.01.049
   PubMed Web of Science ®Google Scholar
• Singh S, Kumar S, Srivastava RK, Nandi A, Thacker G, Murali H, Kim S, Baldeon M, Tobias J, Blanco MA, et al. Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-gamma signalling. Nat Cell Biol. 2020;22(5):591–602.
   PubMed Web of Science ®Google Scholar
• Ben W, Zhang G, Huang Y, Sun Y. MiR-27a-3p regulated the aggressive phenotypes of cervical cancer by targeting FBXW7. Cancer Manag Res. 2020;12:2925–35. 10.2147/CMAR.S234897
   PubMed Web of Science ®Google Scholar
• Zhang P, Shao Y, Quan F, Liu L, Yang J. FBP1 enhances the radiosensitivity by suppressing glycolysis via the FBXW7/mTOR axis in nasopharyngeal carcinoma cells. Life Sci. 2021;283(119840):119840.
   PubMed Web of Science ®Google Scholar
• Zhou YX, Zhang H, Peng C. Puerarin: a review of pharmacological effects. Phytother Res. 2014;28(7):961–75.
   PubMed Web of Science ®Google Scholar
• Huang P, Du SX. Puerarin enhances the anti-tumor effect of cisplatin on drug-resistant A549 cancer in vivo and in vitro through activation of the Wnt signaling pathway. Cancer Manag Res. 2020;12:6279–89. 10.2147/CMAR.S253327
   PubMed Web of Science ®Google Scholar
• Du LJ, Zhang L, Sun F. Puerarin inhibits the progression of bladder cancer by regulating circ_0020394/miR-328-3p/NRBP1 axis. Cancer Biother Radiopharm. 2022;37(6):435–450. doi: 10.1089/cbr.2019.3382
   PubMed Web of Science ®Google Scholar
• Dayarathne LA, Ranaweera SS, Natraj P, Rajan P, Lee YJ, Han CH. The effects of naringenin and naringin on the glucose uptake and AMPK phosphorylation in high glucose treated HepG2 cells. J Vet Sci. 2021;22(6):e92. 10.4142/jvs.2021.22.e92
   PubMed Web of Science ®Google Scholar
• Li FL, Liu JP, Bao RX, Yan G, Feng X, Xu YP, Sun YP, Yan W, Ling ZQ, Xiong Y, et al. Acetylation accumulates PFKFB3 in cytoplasm to promote glycolysis and protects cells from cisplatin-induced apoptosis. Nat Commun. 2018;9(1):508.
   PubMed Web of Science ®Google Scholar
• Naganawa Y, Ishiguro H, Kuwabara Y, Kimura M, Mitsui A, Katada T, Tanaka T, Shiozaki M, Fujii Y, Takeyama H. Decreased expression of FBXW7 is correlated with poor prognosis in patients with esophageal squamous cell carcinoma. Exp Ther Med. 2010;1(5):841–6. 10.3892/etm.2010.115
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang F, Zeng Y, Zhu X, Peng L, Zhang L, Gu J, Han H, Yi X, Shi J. Salicylate sensitizes oral squamous cell carcinoma to chemotherapy through targeting mTOR pathway. Oral Dis. 2020;26(6):1131–40. doi: 10.1111/odi.13345.
   PubMed Web of Science ®Google Scholar
• Choi HS, Kim YK, Yun PY. Cisplatin plus cetuximab inhibits cisplatin-resistant human oral squamous cell carcinoma cell migration and proliferation but does not enhance apoptosis. IJMS. 2021;22(15):8167. 10.3390/ijms22158167
   Web of Science ®Google Scholar
• Shaaban S, Shabana SM, Al-Faiyz YS, Manolikakes G, El-Senduny FF. Enhancing the chemosensitivity of HepG2 cells towards cisplatin by organoselenium pseudopeptides. Bioorg Chem. 2021;109:104713. 10.1016/j.bioorg.2021.104713
   PubMed Web of Science ®Google Scholar
• Li S, Wu C, Fan C, Zhang P, Yu G, Li K. Tanshinone II A improves the chemosensitivity of breast cancer cells to doxorubicin by inhibiting beta-catenin nuclear translocation. J Biochem Mol Toxicol. 2021;35(1):e22620.
   PubMed Web of Science ®Google Scholar
• Wang X, Zhang H, Yang H, Bai M, Ning T, Deng T, Liu R, Fan Q, Zhu K, Li J, et al. Exosome-delivered circRNA promotes glycolysis to induce chemoresistance through the miR-122-PKM2 axis in colorectal cancer. Mol Oncol. 2020;14(3):539–55.
   PubMed Web of Science ®Google Scholar
• Gao W, Zhang Y, Luo H, Niu M, Zheng X, Hu W, Cui J, Xue X, Bo Y, Dai F, et al. Targeting SKA3 suppresses the proliferation and chemoresistance of laryngeal squamous cell carcinoma via impairing PLK1-AKT axis-mediated glycolysis. Cell Death Dis. 2020;11(10):919.
   PubMed Web of Science ®Google Scholar
• Lin H, Zhang L, Zhang C, Liu P. Exosomal MiR-500a-3p promotes cisplatin resistance and stemness via negatively regulating FBXW7 in gastric cancer. J Cell Mol Med. 2020;24(16):8930–41.
   PubMed Web of Science ®Google Scholar
• Wang H, Chen J, Zhang S, Zheng X, Xie S, Mao J, Cai Y, Lu X, Hu L, Shen J, et al. MiR-223 regulates autophagy associated with cisplatin resistance by targeting FBXW7 in human non-small cell lung cancer. Cancer Cell Int. 2020;20:258.
   PubMed Web of Science ®Google Scholar
• Mori A, Masuda K, Ohtsuka H, Shijo M, Ariake K, Fukase K, Sakata N, Mizuma M, Morikawa T, Hayashi H, et al. FBXW7 modulates malignant potential and cisplatin-induced apoptosis in cholangiocarcinoma through NOTCH1 and MCL1. Cancer Sci. 2018;109(12):3883–95.
   PubMed Web of Science ®Google Scholar
• Magaway C, Kim E, Jacinto E. Targeting mTOR and metabolism in cancer: lessons and innovations. Cells. 2019;8(12):1584. 10.3390/cells8121584
   PubMed Web of Science ®Google Scholar
• Courtnay R, Ngo DC, Malik N, Ververis K, Tortorella SM, Karagiannis TC. Cancer metabolism and the Warburg effect: the role of HIF-1 and PI3K. Mol Biol Rep. 2015;42(4):841–51. 10.1007/s11033-015-3858-x
   PubMed Web of Science ®Google Scholar
• Li J, Cheng D, Zhu M, Yu H, Pan Z, Liu L, Geng Q, Pan H, Yan M, Yao M. OTUB2 stabilizes U2AF2 to promote the Warburg effect and tumorigenesis via the AKT/mTOR signaling pathway in non-small cell lung cancer. Theranostics. 2019;9(1):179–95.
   PubMed Web of Science ®Google Scholar
• Balamurugan K, Wang JM, Tsai HH, Sharan S, Anver M, Leighty R, Sterneck E. The tumour suppressor C/EBPdelta inhibits FBXW7 expression and promotes mammary tumour metastasis. Embo J. 2010;29(24):4106–17. 10.1038/emboj.2010.280
   PubMed Web of Science ®Google Scholar
• Yeh CH, Bellon M, Nicot C. FBXW7: a critical tumor suppressor of human cancers. Mol Cancer. 2018;17(1):115. 10.1186/s12943-018-0857-2
   PubMed Web of Science ®Google Scholar
• Gstalder C, Liu D, Miao D, Lutterbach B, DeVine AL, Lin C, Shettigar M, Pancholi P, Buchbinder EI, Carter SL, et al. Inactivation of Fbxw7 impairs dsRNA sensing and confers resistance to PD-1 blockade. Cancer Discov. 2020;10(9):1296–311.
   PubMed Web of Science ®Google Scholar
• Wang H, Lu Y, Wang M, Wu Y, Wang X, Li Y. Roles of E3 ubiquitin ligases in gastric cancer carcinogenesis and their effects on cisplatin resistance. J Mol Med (Berl). 2021;99(2):193–212. 10.1007/s00109-020-02015-5
   PubMed Web of Science ®Google Scholar
• Zhu H, Xiao Y, Guo H, Guo Y, Huang Y, Shan Y, Bai Y, Lin X, Lu H. The isoflavone puerarin exerts anti-tumor activity in pancreatic ductal adenocarcinoma by suppressing mTOR-mediated glucose metabolism. Aging (Albany NY). 2021;13(23):25089–105.
   PubMedGoogle Scholar
• Jiang K, Chen H, Tang K, Guan W, Zhou H, Guo X, Chen Z, Ye Z, Xu H. Puerarin inhibits bladder cancer cell proliferation through the mTOR/p70S6K signaling pathway. Oncol Lett. 2018;15(1):167–74.
   PubMed Web of Science ®Google Scholar
• Wu Z, Wu J, Fang P, Kan S. Puerarin increases the chemosensitivity of hepatocellular carcinoma cells. Oncol Lett. 2017;14(3):3006–10.
   PubMed Web of Science ®Google Scholar
• Belmonte-Fernández A, Herrero-Ruíz J, Galindo-Moreno M, Limón-Mortés MC, Mora-Santos M, Sáez C, Japón MÁ, Tortolero M, Romero F. Cisplatin-induced cell death increases the degradation of the MRE11-RAD50-NBS1 complex through the autophagy/lysosomal pathway. Cell Death Differ. 2022; doi: 10.1038/s41418-022-01100-1.
   PubMed Web of Science ®Google Scholar
• Yin L, Zhang J, Sun Y. Early growth response-1 is a new substrate of the GSK3β-FBXW7 axis. Neoplasia. 2022;34(100839):100839.
   PubMed Web of Science ®Google Scholar
• Chen ZQ, Zhou Y, Huang JW, Chen F, Zheng J, Li HL, Li T, Li L. Puerarin pretreatment attenuates cardiomyocyte apoptosis induced by coronary microembolization in rats by activating the PI3K/Akt/GSK-3β signaling pathway. Korean J Physiol Pharmacol. 2021;25(2):147–57.
   PubMed Web of Science ®Google Scholar